Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018061012) A UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/061012 International Application No.: PCT/IL2017/051102
Publication Date: 05.04.2018 International Filing Date: 28.09.2017
IPC:
C12N 5/10 (2006.01) ,A61P 35/00 (2006.01) ,A61K 35/17 (2015.01) ,C07K 14/705 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
[IPC code unknown for A61K 35/17]
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
Applicants:
GAVISH-GALILEE BIO APPLICATIONS LTD. [IL/IL]; P.O. Box 831 1101602 Kiryat Shmona, IL
IMMPACT-BIO LTD. [IL/IL]; IL
Inventors:
GROSS, Gideon; IL
BEIMAN, Merav; IL
GIBSON, William; US
Agent:
SCHWARZ, Mikael; IL
Priority Data:
62/400,73728.09.2016US
Title (EN) A UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCER
(FR) PLATE-FORME UNIVERSELLE POUR THÉRAPIE CAR CIBLANT UNE NOUVELLE SIGNATURE ANTIGÉNIQUE DU CANCER
Abstract:
(EN) A nucleic acid molecule comprising a nucleotide sequence encoding an inhibitory chimeric antigen receptor (i CAR) capable of preventing or attenuating undesired activation of an effector immune cell, wherein the i CAR comprises an extracellular domain that specifically binds to a single allelic variant of a polymorphic cell surface epitope absent from mammalian tumor cells due to loss of heterozygosity (LOH) but present at least on all cells of related mammalian normal tissue; and an intracellular domain comprising at least one signal transduction element that inhibits an effector immune cell is provided. Vectors and transduced effector immune cells comprising the nucleic acid molecule and methods for treatment of cancer comprising administering the transduced effector immune cells are further provided.
(FR) L'invention concerne une molécule d'acide nucléique qui comprend une séquence de nucléotides codant pour un récepteur antigénique chimérique inhibiteur (iCAR) capable de prévenir ou d'atténuer l'activation indésirable d'une cellule immunitaire effectrice, le iCAR comprenant un domaine extracellulaire qui se lie spécifiquement à un variant allélique unique d'épitope de surface cellulaire polymorphe absent des cellules tumorales mammaliennes en raison de la perte d'hétérozygosité (LOH) mais présent au moins sur toutes les cellules du tissu mammalien normal associé ; et un domaine intracellulaire comprenant au moins un élément de transduction de signal qui inhibe une cellule immunitaire effectrice. Des vecteurs et des cellules immunitaires effectrices transduites comprenant la molécule d'acide nucléique et des méthodes de traitement du cancer comprenant l'administration desdites cellules immunitaires effectrices transduites sont en outre décrits.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)